Nilotinib Hydrochloride
TASIGNA®

About TASIGNA®
-
Marketed by Novartis Pharmaceuticals Corporation
-
Orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor
-
Treatment of adult and pediatric patients with newly diagnosed or treatment-resistant Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML)
Review and approval status
November 19, 2007
First E.U. approval
October 29, 2007
First U.S. approval
Actual and expected launch:
- 2023: Patent expiry: United States
- 2023: Patent expiry: European Union
- 2028: Patent expiry: Japan
API availability

